Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alprazolam extended-release in panic disorder.

Karl Rickels1

  • 1University of Pennsylvania, Department of Psychiatry, University of Pennsylvania Medical Center, PA 19104-3309, USA. krickels@mail.med.upenn.edu

Expert Opinion on Pharmacotherapy
|June 24, 2004
PubMed
Summary

Alprazolam-XR offers comparable anti-panic efficacy to standard alprazolam but with improved tolerability and safety. This extended-release formulation may reduce abuse potential and adverse events like sedation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The rise and fall and rise of benzodiazepines: a return of the stigmatized and repressed.

Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)·2020
Same author

Benzodiazepines, antidepressants and addiction: A plea for conceptual rigor and consistency.

Journal of psychopharmacology (Oxford, England)·2019
Same author

The Course of Adverse Events in Venlafaxine XR Treatment in Generalized Anxiety Disorder.

Journal of clinical psychopharmacology·2019
Same author

Benzodiazepines in anxiety disorders: Reassessment of usefulness and safety.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry·2018
Same author

The Prescription of Benzodiazepines for Panic Disorder: Time for an Evidence-Based Educational Approach.

Journal of clinical psychopharmacology·2018
Same author

Vilazodone, a novel, dual-acting antidepressant: current status, future promise and potential for individualized treatment of depression.

Personalized medicine·2018

Area of Science:

  • Pharmacology
  • Psychiatry

Background:

  • Alprazolam is a high-potency benzodiazepine used for panic disorder.
  • Standard alprazolam formulations can lead to rapid peak plasma concentrations, potentially increasing abuse liability and adverse events.

Purpose of the Study:

  • To evaluate the efficacy, tolerability, and safety of alprazolam-XR, an extended-release formulation.
  • To compare the pharmacokinetic profile and clinical outcomes of alprazolam-XR with immediate-release alprazolam.

Main Methods:

  • Pharmacokinetic analysis of alprazolam-XR to assess plasma concentration profiles over 24 hours.
  • Clinical assessment of anti-panic efficacy and adverse events compared to standard alprazolam.

Main Results:

  • Alprazolam-XR demonstrated sustained therapeutic concentrations with once-daily dosing.
  • Anti-panic efficacy was comparable to immediate-release alprazolam.
  • Alprazolam-XR showed reduced incidence of sedation and cognitive/psychomotor impairment, suggesting a more favorable benefit:risk profile.

Conclusions:

  • Alprazolam-XR offers a potentially safer and better-tolerated alternative for panic disorder management.
  • Once-daily dosing enhances patient compliance and reduces breakthrough anxiety.
  • Long-term risks of dependence and withdrawal remain similar to the original formulation.

Related Experiment Videos